Press Releases Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
46.6 ^USD	-0.89%		+7.13%	+671.52%

Jun. 03	Corbus Pharmaceuticals Reaches 2-Year High After Drug Results	DJ
Jun. 03	Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $80 From $60, Maintains Outperform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024	Jun. 01	AQ
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference	May. 30	AQ
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting	May. 23	AQ
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference	May. 09	AQ
Corbus Pharmaceuticals: Q1 Earnings Snapshot	May. 07	AQ
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 07	AQ
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum	May. 01	AQ
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting	Apr. 24	AQ
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	Apr. 02	AQ
Corbus Pharmaceuticals: Q4 Earnings Snapshot	Mar. 12	AQ
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	Mar. 12	AQ
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit	Mar. 06	AQ
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer	Feb. 28	AQ
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	AQ
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares	Feb. 02	AQ
Corbus Pharmaceuticals Announces Pricing of Public Offering	Jan. 31	AQ
Corbus Pharmaceuticals Announces Proposed Public Offering	Jan. 30	AQ
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate	Jan. 29	AQ
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024	Jan. 26	AQ
Corbus Pharmaceuticals - Phase 1 Clinical Data for SYS6002 to be presented at 2024 ASCO GU	Jan. 24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Press Releases

Filters